Aquinox plans to conduct $75 million public offering of common stock

Bookrunners Leerink Partners, Canaccord Genuity and Guggenheim assist

By Devika Patel

Knoxville, Tenn., Sept. 8 – Aquinox Pharmaceuticals, Inc. plans to price a $75 million public sale of common stock with a 30-day $11.25 million greenshoe, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Leerink Partners, Canaccord Genuity and Guggenheim Securities are the bookrunners, and Needham & Co. is the lead manager.

Proceeds will be used for phase 3 trials for AQX-1125, research and development, working capital and other general corporate purposes.

The clinical-stage pharmaceutical company is based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.